TEE
CBAY

Tibra Equities Europe’s Cymabay Therapeutics CBAY Stock Holding History

Tibra Equities Europe’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-60,800
Closed -$349K – 142
2020
Q4 		$349K Buy
+60,800
New +$460K 0.04% 129
2019
Q2 		– Sell
-65,800
Closed -$874K – 467
2019
Q1 		$874K Buy
+65,800
New +$700K 0.09% 184
2018
Q2 		– Sell
-120,597
Closed -$1.57M – 223
2018
Q1 		$1.57M Buy
+120,597
New +$1.5M 0.27% 58

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Tibra Equities Europe's CBAY Position: Q1 2021 in Review

Tibra Equities Europe sold out of Cymabay Therapeutics (CBAY) in Q1 2021, closing a stake of 60,800 shares — an estimated $349K sold.

Tibra Equities Europe first reported a position in CBAY in Q1 2018 and held it in 3 quarters. The position peaked at $1.57M in Q1 2018. 130 funds tracked by Wall St. Rank hold CBAY as of Q1 2021.

  • Tibra Equities Europe reported no remaining Cymabay Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Tibra Equities Europe sold 60,800 Cymabay Therapeutics shares in Q1 2021, an estimated $349K.
  • Tibra Equities Europe first reported a position in Cymabay Therapeutics in Q1 2018 and held it in 3 quarters.
  • Tibra Equities Europe's Cymabay Therapeutics position peaked at $1.57M in Q1 2018.
  • 130 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2021.

Based on Tibra Equities Europe's 13F filing for Q1 2021, filed 17 May 2021.